File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Integrin-linked kinase promotes hepatocellular carcinoma oncogenesis

TitleIntegrin-linked kinase promotes hepatocellular carcinoma oncogenesis
Authors
KeywordsMedical sciences
Oncology
Issue Date2010
PublisherElsevier BV. The Journal's web site is located at www.ejcancer.info/supplements
Citation
The 21st Meeting of the European Association for Cancer Research (EACR 2010), Oslo, Norway, 26-29 June 2010. In European Journal of Cancer Supplements, 2010, v. 8 n. 5, p. 183-184, abstract no. 727 How to Cite?
AbstractBACKGROUND: Integrin-linked kinase (ILK) was first discovered as an integrin binding protein. It localizes to focal adhesions and facilitates actin polymerization. Accumulating evidences suggest that ILK is a putative oncogene. ILK was over-expressed in various malignancies and its aberrant activation influenced a wide range of cellular functions. In this study, we aimed to elucidate the role of ILK in hepatocarcinogenesis and its clinical significance by assessing ILK expression in human hepatocellular carcinoma (HCC) tissues and functionally characterizing ILK in HCC cell models. MATERIAL AND METHODS: Expression level of ILK in HCC cell lines was examined by Western blotting, while ILK expression in clinical samples was determined by quantitative PCR. ILK knock-down stable clones were established in BEL7402 and HLE using a lentiviral-based short-hairpin knockdown approach. For each cell line, two stable ILK knock-down (shILK) clones and one stable non-target control (shCTL) were established. To functionally characterize ILK in HCC, the knock-down stable clones were subjected to various functional assays including cell proliferation assay, soft agar colony formation assay, cell migration assay, wound-healing assay and cell invasion assay. In vivo tumourigenicity of BEL7402 ILK knock-down stable clones was assessed by subcutaneous injection of the cells into nude mice. RESULTS: Western blotting revealed a higher ILK protein expression in HCC cell lines than in normal liver cell line. In the physiological context, qPCR analysis showed that ILK was over-expressed in 36.9% (21/57) of HCC tissues when compared to the corresponding non-tumourous livers. The overall ILK expression level was significantly higher in tumourous tissues (P = 0.005), with a stepwise increase of expression along tumour stage. Functional characterization of ILK in HCC using the two ILK stable knockdown cell lines showed a reduction in the rate of cell proliferation, migration, invasion and anchorage-independent growth. Knock-down of ILK in BEL7402 also suppressed tumour formation in nude mice, thus decreasing the in vivo tumourigenicity of HCC cells. To probe the underlying mechanism, AKT activity was evaluated in the shILK clones. Western blotting analysis showed a decrease in phospho-AKT(Ser473) level upon ILK silencing. CONCLUSION: Our study suggests that ILK plays a role in the progression of HCC via the activation of the PKB/AKT pathway.
DescriptionPoster Session: Molecular Biology
Persistent Identifierhttp://hdl.handle.net/10722/126703
ISSN
2010 Impact Factor: 9.386
2023 SCImago Journal Rankings: 0.759
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChan, Jen_HK
dc.contributor.authorKo, FCFen_HK
dc.contributor.authorNg, IOLen_HK
dc.contributor.authorYam, JWPen_HK
dc.date.accessioned2010-10-31T12:43:38Z-
dc.date.available2010-10-31T12:43:38Z-
dc.date.issued2010en_HK
dc.identifier.citationThe 21st Meeting of the European Association for Cancer Research (EACR 2010), Oslo, Norway, 26-29 June 2010. In European Journal of Cancer Supplements, 2010, v. 8 n. 5, p. 183-184, abstract no. 727en_HK
dc.identifier.issn1359-6349-
dc.identifier.urihttp://hdl.handle.net/10722/126703-
dc.descriptionPoster Session: Molecular Biology-
dc.description.abstractBACKGROUND: Integrin-linked kinase (ILK) was first discovered as an integrin binding protein. It localizes to focal adhesions and facilitates actin polymerization. Accumulating evidences suggest that ILK is a putative oncogene. ILK was over-expressed in various malignancies and its aberrant activation influenced a wide range of cellular functions. In this study, we aimed to elucidate the role of ILK in hepatocarcinogenesis and its clinical significance by assessing ILK expression in human hepatocellular carcinoma (HCC) tissues and functionally characterizing ILK in HCC cell models. MATERIAL AND METHODS: Expression level of ILK in HCC cell lines was examined by Western blotting, while ILK expression in clinical samples was determined by quantitative PCR. ILK knock-down stable clones were established in BEL7402 and HLE using a lentiviral-based short-hairpin knockdown approach. For each cell line, two stable ILK knock-down (shILK) clones and one stable non-target control (shCTL) were established. To functionally characterize ILK in HCC, the knock-down stable clones were subjected to various functional assays including cell proliferation assay, soft agar colony formation assay, cell migration assay, wound-healing assay and cell invasion assay. In vivo tumourigenicity of BEL7402 ILK knock-down stable clones was assessed by subcutaneous injection of the cells into nude mice. RESULTS: Western blotting revealed a higher ILK protein expression in HCC cell lines than in normal liver cell line. In the physiological context, qPCR analysis showed that ILK was over-expressed in 36.9% (21/57) of HCC tissues when compared to the corresponding non-tumourous livers. The overall ILK expression level was significantly higher in tumourous tissues (P = 0.005), with a stepwise increase of expression along tumour stage. Functional characterization of ILK in HCC using the two ILK stable knockdown cell lines showed a reduction in the rate of cell proliferation, migration, invasion and anchorage-independent growth. Knock-down of ILK in BEL7402 also suppressed tumour formation in nude mice, thus decreasing the in vivo tumourigenicity of HCC cells. To probe the underlying mechanism, AKT activity was evaluated in the shILK clones. Western blotting analysis showed a decrease in phospho-AKT(Ser473) level upon ILK silencing. CONCLUSION: Our study suggests that ILK plays a role in the progression of HCC via the activation of the PKB/AKT pathway.-
dc.languageengen_HK
dc.publisherElsevier BV. The Journal's web site is located at www.ejcancer.info/supplements-
dc.relation.ispartofEuropean Journal of Cancer Supplements-
dc.subjectMedical sciences-
dc.subjectOncology-
dc.titleIntegrin-linked kinase promotes hepatocellular carcinoma oncogenesisen_HK
dc.typeConference_Paperen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1359-6349&volume=8&issue=5&spage=183&epage=184, abstract no. 727&date=2010&atitle=Integrin-linked+kinase+promotes+hepatocellular+carcinoma+oncogenesis-
dc.identifier.emailKo, FCF: bokcf@hkucc.hku.hken_HK
dc.identifier.emailNg, IOL: iolng@hkucc.hku.hken_HK
dc.identifier.emailYam, JWP: judyyam@pathology.hku.hken_HK
dc.identifier.authorityNg, IOL=rp00335en_HK
dc.identifier.authorityYam, JWP=rp00468en_HK
dc.identifier.doi10.1016/S1359-6349(10)71524-X-
dc.identifier.hkuros172258en_HK
dc.identifier.volume8-
dc.identifier.issue5-
dc.identifier.spage183, abstract no. 727-
dc.identifier.epage184-
dc.identifier.isiWOS:000288603100702-
dc.description.otherThe 21st Meeting of the European Association for Cancer Research (EACR), Oslo, Norway, 26-29 June 2010. In European Journal of Cancer Supplements, 2010, v. 8 n. 5, p. 183-184, abstract no. 727-
dc.identifier.issnl1359-6349-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats